Q2 2023 Y-mAbs Therapeutics Inc Earnings Call Transcript
Good morning, and welcome to the Y-mAbs Therapeutics Inc.'s Earnings Conference Call for the second quarter of 2023. (Operator Instructions) As a reminder, today's conference will be recorded. I will now hand it over to Y-mAbs' Head of IR, Courtney Dugan.
Thank you, Courtney, and good morning, everyone, and thank you. Let me quickly remind you that the following discussion contains certain statements that are considered forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about our business model and development, commercialization and product distribution plans, current and future clinical and preclinical studies and our research and development programs; expectations related to the timing of the initiation and completion of regulatory submissions, regulatory, marketing and reimbursement approvals, including statements with respect to future development of other development programs, potential for DANYELZA territory expansion and advancement of SADA
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |